CFM
LYRA

Catalyst Funds Management’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Catalyst Funds Management’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-164
Closed -$51K – 1415
2024
Q1 		$51K Buy
+164
New +$43.7K 0.01% 553

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalyst Funds Management's LYRA Position: Q2 2024 in Review

Catalyst Funds Management sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2024, closing a stake of 164 shares — an estimated $51K sold.

Catalyst Funds Management first reported a position in LYRA in Q1 2024 and held it in 1 quarter. The position peaked at $51K in Q1 2024. 51 funds tracked by Wall St. Rank hold LYRA as of Q2 2024.

  • Catalyst Funds Management reported no remaining LYRA THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 164 LYRA THERAPEUTICS INC shares in Q2 2024, an estimated $51K.
  • Catalyst Funds Management first reported a position in LYRA THERAPEUTICS INC in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's LYRA THERAPEUTICS INC position peaked at $51K in Q1 2024.
  • 51 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.